Intensive Stem Cell Transplant Conditioning with Thiotepa, Busulfan, Fludarabine, and Cytarabine for Myeloid Cancers with Tumors Outside the Bone Marrow
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2024-07-22
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an intensive conditioning regimen combining thiotepa, busulfan, fludarabine, and cytarabine for patients undergoing allogeneic hematopoietic stem cell transplantation to treat myeloid malignancies with extramedullary involvement. This single-arm, prospective phase II trial aims to assess the regimens efficacy and safety, focusing on progression-free survival and other post-transplant outcomes. The study is led by Shanghai General Hospital and targets adults aged 18 to 55 with specific myeloid tumor conditions.
The treatment involves a conditioning phase starting nine days before the stem cell infusion, with thiotepa given on days -9 and -8, fludarabine and cytarabine from days -7 to -3, and busulfan from days -5 to -3. Donor stem cells are infused on day 0. After transplantation, patients will undergo bone marrow examinations on days 14 and 28, followed by regular checks every 30 days during the first year and every 60 days in the second year. Additional assessments will be performed if relapse is suspected.
Participants will be closely monitored for outcomes including progression-free survival at one and two years, overall survival, incidence of acute and chronic graft-versus-host disease, relapse rates, and viral reactivation. The study includes laboratory tests, bone marrow biopsies, and regular clinical evaluations to track health status and treatment effects over time. Follow-up extends up to two years post-transplant to capture long-term outcomes and safety data.
CONDITIONS
Brief Title
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Research Team
X
Xianmin Song, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor
Who Can Participate
Age: 18Years - 55Years
All Genders
Eligibility Criteria
You may qualify if you...
Age between 18 and less than 55 years, any gender
Diagnosis of myeloid tumors with extramedullary involvement, including AML, MDS, CMML, or granulocytic sarcoma in remission
Achieved hematological remission after treatment for extramedullary lesions
Suitable hematopoietic stem cell donor with required HLA match (related: at least 5/10; unrelated: at least 8/10)
Hematopoietic cell transplantation comorbidity index (HCT-CI) score of 2 or less
ECOG performance status between 0 and 2
Adequate liver, kidney, heart, and lung function meeting specified laboratory and clinical criteria
Ability to understand and willing to sign informed consent
You will not qualify if you...
History of malignancies other than myeloid tumors within 5 years, except certain treated localized cancers
ECOG performance status greater than 2
HCT-CI score 3 or higher
Unstable systemic diseases including recent heart or cerebrovascular events, severe heart failure, arrhythmias, significant liver, kidney, metabolic or pulmonary diseases
Active uncontrolled infections or persistent unexplained fever
Neurological or psychiatric conditions requiring treatment, such as seizures or severe brain injury
HIV infection
Active hepatitis B or C requiring antiviral therapy or risk of hepatitis B reactivation without treatment
Pregnant or breastfeeding women
Fertile males and females unwilling to use contraception during treatment and for 12 months after treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 2 years
Participants are observed over time to assess disease progression, survival, and complications following stem cell transplantation.
Regular visits over 1 to 2 years
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Study of Escalating Doses of 211-At-BC8-B10 Followed by Donor Stem Cell Transplant for High-Risk AML, ALL, MDS, or Mixed-Phenotype Acute Leukemia
Study of 211At-BC8-B10 Antibody Followed by Donor Stem Cell Transplant in Adults 18 to 75 With High-Risk or Relapsed Acute Leukemia and Myelodysplastic Syndrome
Phase I Dose Escalation Study of 225Ac-DOTA-Anti-CD38 Daratumumab Added to Fludarabine, Melphalan, and Targeted Total Marrow and Lymphoid Irradiation Before Donor Stem Cell Transplant for High-Risk Leukemia and Myelodysplastic Syndrome
Phase I Study of CLL1 and CD38 Dual-Target CAR-T Cell Injection for Safety and Preliminary Effectiveness in Adults with Relapsed or Refractory Acute Myeloid Leukemia
Study of CD33 CAR-T Cell Therapy for Safety and Effectiveness in Adults with Relapsed or Refractory Acute Myeloid Leukemia
Home-Based CAREFit-BMT Exercise Program to Improve Heart Function in High-Risk Acute Myeloid Leukemia Patients Preparing for Stem Cell Transplant
Study of ASTX030 Azacitidine and Cedazuridine Alone or with Venetoclax for Treatment of Myeloid Neoplasms and AML
Phase III Study of Venetoclax and Revumenib Combination for Treating Minimal Residual Disease in Acute Myeloid Leukemia
Comparing Venetoclax Plus CACAG Versus Standard 37 Chemotherapy in Adults Aged 14 to 75 With Intermediate- or High-Risk Acute Myeloid Leukemia
Study of Ivosidenib with Venetoclax and Azacitidine for Adults with Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.
Gheath Alatrash, Marcos de Lima, Nelson Hamerschlak...
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Federica Sora, Carmen Di Grazia, Patrizia Chiusolo...
Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia.